CJC-1295 research guide for Kanavy. Covers DAC vs no-DAC forms, half-life differences, purity testing, and how to source quality CJC-1295 for research.
For anyone in Kanavy trying to locate CJC-1295, the foundational reality is that this compound is distributed via specialist online vendors. What this means for Kanavy researchers is that your location matters far less than your ability to verify analytical documentation — and those evaluation tools are within reach of all serious researchers. A properly operating CJC-1295 supplier's COA must contain HPLC purity, mass spectrometry confirmation of molecular identity, bacterial endotoxin testing, and a residual solvents panel — all corresponding to the vial you receive. The sections below cover what Kanavy researchers need to know about purchasing, testing, and working with CJC-1295 for research purposes.
Understanding CJC-1295 — Biology & Evidence
CJC-1295 with DAC (Drug Affinity Complex) is a GHRH analogue with an extended half-life achieved through DAC technology that enables covalent binding to albumin. This modification extends the half-life from minutes (for native GHRH) to approximately 6-8 days, creating a sustained elevation in basal GH levels rather than the pulsatile pattern produced by GHRP compounds. This pharmacokinetic distinction is significant for research design: CJC-1295 based on CJC-1295 with DAC produces a different GH secretion pattern than GHRP compounds, with different downstream effects on IGF-1 and protein synthesis. Researchers in Kanavy comparing compounds in this class should account for these pharmacokinetic differences in their experimental design.
Buying CJC-1295: Quality Markers to Look For
Before evaluating any specific vendor, understand what genuine quality documentation contains — so you can recognise whether a vendor meets it. When reviewing a CJC-1295 COA, verify: the batch number corresponds to your vial, HPLC purity is ≥98%, mass spec establishes identity, and endotoxin levels are below the threshold for research use. Strong quality indicators beyond COA quality: multi-year operating history, customer service that can discuss analytical methods, and shipping with desiccant and appropriate cold protection. For Kanavy researchers making a first CJC-1295 purchase: work through this evaluation framework first, order conservatively at first, and confirm the COA batch number matches your received product before use.
Order CJC-1295 — ships to Kanavy
COA-verified · International tracking · Research grade
CJC-1295 operates outside approved pharmaceutical regulation — researchers should understand that the risk characterisation for this compound is based on academic studies rather than pharmaceutical approval data. Proper handling of CJC-1295 requires careful sterile procedure — alcohol-swabbed septum, fresh needles, clean working environment — and consistent cold chain handling. The most significant preventable safety hazard in CJC-1295 research is endotoxin from inadequately tested product — a verified endotoxin panel in the batch COA is the key safeguard. Researchers using CJC-1295 alongside other research compounds should check the research literature for any reported interactions before beginning combination research.
Frequently Asked Questions
What is the difference between CJC-1295 with DAC and without DAC?
CJC-1295 with DAC uses a lysine-maleimide conjugate to bind covalently to albumin in the bloodstream, extending half-life to ~6-8 days and creating sustained GH elevation. CJC-1295 without DAC (also called Mod GRF 1-29) has a half-life of ~30 minutes and produces acute GH pulses. They produce different GH secretion patterns and have different applications in research.
What purity is required for CJC-1295 research?
CJC-1295 should be ≥98% pure by HPLC. The larger molecular weight of CJC-1295 with DAC (approximately 3647 Da) makes mass spectrometry confirmation particularly important, as impurities may not be obvious on HPLC alone.
What is CJC-1295?
CJC-1295 is a synthetic GHRH (Growth Hormone Releasing Hormone) analogue. The version with DAC (Drug Affinity Complex) has an extended half-life of approximately 6-8 days due to albumin binding. Without DAC, CJC-1295 has a much shorter half-life similar to native GHRH. Both versions stimulate pulsatile GH release via the GHRH receptor.
